Galmed (GLMD) director discloses multiple stock option grants

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. director Carol L. Brosgart filed an initial ownership report showing she holds several option grants to purchase Ordinary Shares. The options have exercise prices ranging from 1.4100 to 2080.8000 and expiration dates from 2027-04-25 through 2035-10-29. Footnotes state that portions of these options vest in stages between 2026 and 2028, subject to her continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Brosgart Carol L

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	07/15/2021	07/15/2031	Ordinary Shares	111	$558	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	166	$2,080.8	D
Options to Purchase Ordinary Shares	04/25/2017	04/25/2027	Ordinary Shares	166	$876.6	D
Options to Purchase Ordinary Shares	08/07/2023	08/07/2033	Ordinary Shares	6,250(1)	$12.6	D
Options to Purchase Ordinary Shares	11/12/2024	11/12/2034	Ordinary Shares	17,500(2)	$2.88	D
Options to Purchase Ordinary Shares	10/29/2025	10/29/2035	Ordinary Shares	12,500(3)	$1.41	D

Explanation of Responses:

1. These options vest on August 7, 2026, subject to the Reporting Person's continued service.

2. These options vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service.

3. These options vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.

	/s/ Carol L. Brosgart	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Galmed Pharmaceuticals (GLMD) disclose in this Form 3?

Galmed Pharmaceuticals reports director Carol L. Brosgart’s option holdings. The filing lists multiple options to purchase Ordinary Shares with specific exercise prices, expiration dates, and vesting schedules that extend from 2026 through 2035, establishing her initial derivative ownership position.

Who is the reporting person in Galmed Pharmaceuticals (GLMD) Form 3?

The reporting person is Carol L. Brosgart, a director of Galmed. The Form 3 registers her status as an insider and details her beneficial ownership of options to purchase Ordinary Shares, including exercise prices, expiration timelines, and staged vesting conditions.

What stock options does Carol L. Brosgart hold in Galmed (GLMD)?

Brosgart holds several options to purchase Galmed Ordinary Shares. The grants have exercise prices such as 558.0000, 2080.8000, 876.6000, 12.6000, 2.8800, and 1.4100, with corresponding expiration dates between 2027 and 2035.

How do the Galmed (GLMD) options held by Carol L. Brosgart vest?

Several option grants vest over time subject to continued service. Footnotes describe schedules where options vest on specific dates in 2026, and then in installments on later dates in 2027 and 2028, conditional on Brosgart remaining in her role with the company.

Are there any buy or sell transactions in this Galmed (GLMD) Form 3?

No buy or sell trades are reported in this Form 3. The records are categorized as holdings, reflecting existing option positions rather than new purchases, sales, exercises, or gifts, and transaction direction fields are marked as unknown or neutral.

Why is Galmed Pharmaceuticals (GLMD) Form 3 important for investors?

The Form 3 establishes a baseline of insider derivative ownership. It shows which option grants a director currently holds, including strike prices, expirations, and vesting terms, giving investors a reference point for interpreting any future Form 4 or Form 5 transactions.